Clin2
NCT03936998Possibly a fitRecruiting

Study drug for peanut allergy to change immune response

Peanut Allergy

Part of Immune system & allergy clinical trials.

This early-phase study tests VE416, a treatment meant to help reduce peanut allergy reactions by changing how the immune system responds. If you have documented peanut allergy, you may receive the study medicine and, for some people, take part in a supervised peanut “entry challenge.”

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
60 people
Ages
12 years to 55 years
Study type
Interventional

Who can take part

  • Aged 12 to 55, with a documented history of peanut allergy
  • Test shows peanut allergy is real: either a positive peanut skin test or high peanut “IgE” blood test
  • Ara h 2 IgE blood test is above a required level
  • You (or a parent/guardian for teens) can sign consent, and you can assent if age-appropriate
  • If moving into Phase II: you must react to peanut during a supervised entry challenge at a specific dose

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05695261Recruiting· Phase 2
Oral microbiome capsules for peanut allergy in teens

This Phase 2 study tests whether taking capsules made from donor gut microbes is safe and can reduce allergic reactions to peanuts. It involves peanut allergy testing and close follow-up with stool samples and check-ins.

Boston, Massachusetts
NCT04163562Recruiting· Phase 1/Phase 2
Oral peanut treatment trial for people with peanut allergy

This trial tests an oral (by mouth) immune treatment for people with confirmed peanut allergy. It aims to see whether your immune system can become less reactive to peanuts over time, while keeping you safe during testing with careful emergency planning.

Pamplona, Navarre
NCT07117669Recruiting· Phase 1/Phase 2
Testing a new peanut allergy treatment (ENP-501)

This trial tests a new peanut allergy treatment called ENP-501. It aims to see if the medicine can safely help people with peanut allergy become less sensitive to peanuts.

Aurora, Colorado
NCT07349212Recruiting· Phase 1/Phase 2
Study of UKK-0018 for peanut allergy treatment

This trial tests a new immunotherapy called UKK-0018 to treat peanut allergies in adults. The goal is to help your body become less sensitive to peanuts over time.

Camperdown, New South Wales
NCT07015996Recruiting· Phase 2
Tezepelumab for peanut allergy oral immunotherapy

This trial tests whether adding tezepelumab (a biologic drug) to peanut oral immunotherapy can help people with peanut allergy better tolerate small amounts of peanut protein without having an allergic reaction.

Little Rock, Arkansas
NCT05667610Recruiting
Immune and gut diet study for peanut-allergic children

This trial studies whether an immune-supportive diet can improve gut health (gut permeability) in children with confirmed peanut or tree-nut allergy. If you join, the researchers will use allergy testing and gut-related diet approaches to see whether symptoms and gut measures change.

Amsterdam

Hear when a new Peanut Allergy trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.